|
|
Isentress (Raltegravir, MK-0518)
| Brand Name: |
Isentress |
| Generic Name: |
Raltegravir, MK-0518 |
| Adult Single Dose: |
One 400-mg tablet twice daily |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
Integrase Inhibitor |
|
|
|
- An Overview of Isentress (Raltegravir, MK-0518) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Characteristics of Fusion and Integrase Inhibitors, and CCR5 Antagonists (PDF) (January 29, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo
- Isentress (Raltegravir) (January 8, 2008)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Isentress (Raltegravir, RAL, Formerly MK-0518) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Mr. Sharp Goes to Washington (November/December 2007)
Advocating for a new drug before the FDA.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- How Isentress Works: An Interview With David Wohl, M.D. (October 23, 2007)
From The Body
- The Bottom Line on Isentress: An Interview With David Wohl, M.D. (October 23, 2007)
From The Body
- Project Inform Reacts to Approval, Pricing of Isentress (October 15, 2007)
From Project Inform
- FDA Approval of Isentress (Raltegravir) (October 12, 2007)
From U.S. Food and Drug Administration
- Isentress (Raltegravir) Pricing: Community Sign-On Letter (October 11, 2007)
In AIDS Treatment News, from AIDS Treatment News
- Raltegravir (Isentress) (October 5, 2007)
To read PDF, click here
From AIDS InfoNet
- Isentress (Raltegravir, MK-0518) Patient Product Information (PDF) (October 2007)
From Merck & Co., Inc.
- Patient Information About Isentress (Raltegravir, MK-0518) (PDF) (October 2007)
From Merck & Co., Inc.
- ICAAC 2007 Study Summaries: An Interview With Joseph Eron, M.D. (September 20, 2007)
Dr. Eron discusses 48-week results of a study of raltegravir (MK-0518) in highly treatment-experienced HIVers.
From The Body PRO
- Briefing Document (Background Package): Raltegravir (PDF) (September 5, 2007)
FDA Antiviral Drugs Advisory Committee Meeting.
From U.S. Food and Drug Administration
- Cross-Resistance Between Integrase Inhibitors (July 24, 2007)
It appears that virologic failure with one of the current integrase inhibitors is likely to severely limit subsequent treatment options within that class according to a small cohort study. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- Faster Viral Decay With Raltegravir (July 24, 2007)
Treatment with raltegravir (RAL, MK-0518) produces more rapid viral load reductions than efavirenz (EFV, Sustiva, Stocrin) and significantly reduced the magnitude of the second phase of viral decay. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- FDA Grants Speedy Review for First HIV Integrase Inhibitor (June 29, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- 77% of Treatment-Experienced Patients on MK-0518 (raltegravir) Plus OBT Achieve Viral Load of Less Than 400 Copies: A Study Summary From David Cooper, M.D., and Roy Steigbigel, Ph.D. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- 79% of Treatment-Experienced Patients on MK-0518 Plus OBT Achieve Viral Load of Less Than 400 Copies at Week 16 (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- New Experimental Drug Integrase Inhibitor (MK-0518) (October/November 2006)
In Survival News, from AIDS Survival Project
- MK-0518 Demonstrates Potent Efficacy in Patients With Triple-Class-Resistant Virus: 24-Week Results (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- The Integrase Inhibitor MK-0518 Demonstrates a Favorable Lipid Profile (September 27, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- EARMRK: Expanded Access Research Program for MK-0518 (PDF) (August 17, 2006)
From Merck & Co., Inc.
- Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options (August 17, 2006)
Worldwide access program will be conducted along with phase III studies.
To read PDF, click here
From Merck & Co., Inc.
- Potent Antiretroviral Effect Seen With the Integrase Inhibitor MK-0518 as Part of Combination ART in Treatment-Naive, HIV-1-Infected Patients (August 17, 2006)
In XVI International AIDS Conference
- Integrase Inhibitors: The Next Wave? (Spring 2006)
A quick look at MK-518 and GS-9137.
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America
- Integrase Inhibitors (February 25, 2005)
To read PDF, click here
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
|
